SCHEMBL14812968

SCHEMBL14812968

O=C(O)C1CC12CCN(C(=O)Oc1ccccc1)CC2

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 13/20 0.57
TSHR P16473 9/20 0.57
ALDH1A1 P00352 8/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
MAPK1 P28482 6/20 0.57
TP53 P04637 1/20 0.57
CYP1A2 P05177 6/20 0.56
CYP2C19 P33261 5/20 0.56
GAA P10253 1/20 0.55
USP2 O75604 5/20 0.53
CYP2D6 P10635 4/20 0.53
CYP2C9 P11712 7/20 0.52
HIF1A Q16665 2/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
HSD17B10 Q99714 2/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30449070 0.92 CYP3A4 (0.53) CYP3A4TSHRALDH1A1SMN1; SMN2MAPK1
SCHEMBL18838469 0.80 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2CYP2C19CYP2D6CYP2C9
SCHEMBL18838292 0.80 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2CYP2C19CYP2D6CYP2C9
SCHEMBL2798935 0.80 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2CYP2C19CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL18838470 0.79 SMN1; SMN2 (0.60) ALDH1A1SMN1; SMN2CYP2C19CYP2D6CYP2C9
SCHEMBL1286789 0.78 HPGD (0.53) TSHRALDH1A1TP53USP2HPGD
SCHEMBL11882343 0.78 MGLL (0.72) CYP3A4TSHRALDH1A1SMN1; SMN2MAPK1
SCHEMBL26089744 0.77 CYP3A4 (0.64) CYP3A4TSHRALDH1A1SMN1; SMN2MAPK1
SCHEMBL614078 0.77 CYP3A4 (0.59) CYP3A4TSHRALDH1A1SMN1; SMN2MAPK1
SCHEMBL1578826 0.74 ALDH1A1 (0.78) CYP3A4TSHRALDH1A1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3292110-B1 N-PIPERIDIN-4-YL DERIVATIVES MERCK SHARP & DOHME (NL) 2019-08-21 EP disclosed
EP-3292110-A1 N-PIPERIDIN-4-YL DERIVATIVES Merck Sharp & Dohme B.V. (NL) 2018-03-14 EP disclosed
US-8993757-B2 N-piperidin-4-yl derivatives MERCK SHARP & DOHME B.V. (NL) 2015-03-31 US disclosed
US-20140329822-A1 N-PIPERIDIN-4-YL DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2014-11-06 US disclosed
WO-2013041457-A1 N-PIPERIDIN-4-YL DERIVATIVES MSD OSS B.V. (NL) 2013-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329822-A1 N-PIPERIDIN-4-YL DERIVATIVES PGR, CYP19A1, BRCA1 CYP3A4 1734/4885TSHR 1448/4885ALDH1A1 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.